Vectus Biosystems (ASX:VBS) Common Stock : A$38.37 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Common Stock?

Vectus Biosystems's quarterly common stock increased from Dec. 2022 (A$37.57 Mil) to Jun. 2023 (A$38.35 Mil) and increased from Jun. 2023 (A$38.35 Mil) to Dec. 2023 (A$38.37 Mil).

Vectus Biosystems's annual common stock increased from Jun. 2021 (A$24.84 Mil) to Jun. 2022 (A$27.30 Mil) and increased from Jun. 2022 (A$27.30 Mil) to Jun. 2023 (A$38.35 Mil).

Vectus Biosystems Common Stock Historical Data

The historical data trend for Vectus Biosystems's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Common Stock Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Common Stock

Get a 7-Day Free Trial

17.60

17.86

24.84

27.30

38.35

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial											25.32	27.30	37.57	38.35	38.37

Vectus Biosystems Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines